Novo Nordisk A/S Annual Report 2025. 104 rows view the latest nvo 10k form and other securities and exchange commission (sec) filings for novo nordisk a/s (nyse:nvo) at marketbeat. In the first quarter of 2025, novo nordisk successfully completed the flow kidney outcomes trial with semaglutide 1.0 mg.

Here you can find webcasts, presentations and relevant documents from our last novo nordisk annual general meeting. In the first quarter of 2025, novo nordisk successfully completed the flow kidney outcomes trial with semaglutide 1.0 mg.